Die akute lymphatische Leukämie – Diagnostik, Subgruppen und Therapien

Abstract

The acute lymphoblastic leukemia (ALL) is a heterogenous rare malignant disease of lymphoblastic precursor cells. The peak of incidence lies in childhood (5.3/100 000), but the incidence rises again from the age of 50 onwards, showing a second peak at patients > 80 years old (2.3/100 000). The ALL is an acute life-threatening disease which untreated leads to death within a short time. The therapeutic objective is cure. By the characterization of subgroups, their targeted therapy and therapy optimization cure rates could be improved (from less than 10 % in the eighties) to more than 50 – 70 % (depending on the subgroup). To this achievement the approach has contributed with risk adapted therapy protocols, with improved supportive therapy and in particular with taking the minimal residual disease (the most important prognostic factor) as a basis for the therapy decision. Recently, with the new immunotherapies there exist further promising options of targeted therapies.

Die akute lymphatische Leukämie ist eine seltene hämatologische Systemerkrankung, die unbehandelt tödlich verläuft. Ursache ist die maligne Entartung lymphatischer Vorläuferzellen. Wichtig sind die schnelle Diagnosesicherung und die genaue Charakterisierung der Erkrankung. Dieser Beitrag bietet einen Überblick über den aktuellen Stand der Diagnostik, die Subtypen der ALL sowie über die derzeitigen und neuen Therapieoptionen.

Schlüsselwörter

Akute lymphatische Leukämie - Chemotherapie - Stammzelltransplantation - Prognosefaktoren

Key words

acute lymphoblastic leukemia - chemotherapy - stem cell transplantation - prognostic factors

• Literatur

• 1 Gökbuget N. Treatment of Older Patients with Acute Lymphoblastic Leukaemia. Drugs Aging 2018; 35: 11-26 . doi:10.1007/s40266-017-0503-5
• 2 Arber DA, Orazi A, Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-2405 . doi:10.1182/blood-2016-03-643544
• 3 Beldjord K, Chevret S, Asnafi V. et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood 2014;
• 4 Gökbuget N, Baldus CD, Brüggemann M. et al. Akute lymphatische Leukämie (Feb 2018). Im Internet: https://www.onkopedia.com/de/onkopedia/guidelines/akute-lymphatische-leukaemie-all/@@view/html/index.html ; Stand: 01.05.2018
• 5 Hoelzer D, Bassan R, Dombret H. et al. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: 69-82 . doi:10.1093/annonc/mdw025
• 6 Gökbuget N. Treatment recommendation of the European working group for adult ALL. 1st. Edition Bremen: UNI-MED; 2011: 208pp
• 7 Gökbuget N, Baumann A, Beck J. et al. PEG-Asparaginase Intensification In Adult Acute Lymphoblastic Leukemia (ALL): Significant Improvement of Outcome with Moderate Increase of Liver Toxicity In the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003. Blood 2010; 116: Abstract 494
• 8 van Dongen JJ, van der Velden VH, Bruggemann M. et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 2015; 125: 3996-4009 . doi:10.1182/blood-2015-03-580027
• 9 Bruggemann M, Schrauder A, Raff T. et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia 2010; 24: 521-535 . doi:10.1038/leu.2009.268
• 10 Gökbuget N, Kneba M, Raff T. et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012; 120: 1868-1876 . doi:10.1182/blood-2011-09-377713
• 11 Wilke AC, Gökbuget N. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab. Expert Opin Drug Saf 2017; 16: 1191-1202 . doi:10.1080/14740338.2017.1338270
• 12 Kantarjian H, Stein A, Gökbuget N. et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med 2017; 376: 836-847 . doi:10.1056/NEJMoa1609783
• 13 Kantarjian HM, DeAngelo DJ, Stelljes M. et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med 2016; 375: 740-753 . doi:10.1056/NEJMoa1509277
• 14 Kantarjian HM, Stein AS, Bargou RC. et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer 2016; 122: 2178-2185 . doi:10.1002/cncr.30031
• 15 Gökbuget N, Dombret H, Bonifacio M. et al. Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL). Blood 2015; 126: 680 . Accessed July 24, 2018. Retrieved from http://www.bloodjournal.org/content/126/23/680
• 16 Gökbuget N, Dombret H, Bonifacio M. et al. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. Blood 2018;